175.78
Schlusskurs vom Vortag:
$176.90
Offen:
$177.25
24-Stunden-Volumen:
313.69K
Relative Volume:
0.66
Marktkapitalisierung:
$10.39B
Einnahmen:
$393.98M
Nettoeinkommen (Verlust:
$-367.45M
KGV:
-27.93
EPS:
-6.293
Netto-Cashflow:
$-460.07M
1W Leistung:
-1.09%
1M Leistung:
+8.51%
6M Leistung:
+25.83%
1J Leistung:
+37.49%
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Firmenname
Ascendis Pharma A S Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ASND mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ASND
Ascendis Pharma A S Adr
|
175.78 | 10.39B | 393.98M | -367.45M | -460.07M | -6.293 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.54 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
511.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
313.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
540.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
257.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2025-04-16 | Eingeleitet | RBC Capital Mkts | Outperform |
2025-01-07 | Eingeleitet | UBS | Buy |
2024-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
2024-06-25 | Hochstufung | TD Cowen | Hold → Buy |
2024-05-31 | Eingeleitet | Stifel | Buy |
2023-12-20 | Eingeleitet | Jefferies | Buy |
2023-06-14 | Fortgesetzt | Credit Suisse | Neutral |
2023-04-05 | Herabstufung | Oppenheimer | Outperform → Perform |
2023-04-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2023-04-03 | Herabstufung | Credit Suisse | Outperform → Neutral |
2022-10-20 | Eingeleitet | Goldman | Buy |
2022-08-30 | Fortgesetzt | Berenberg | Buy |
2022-03-28 | Fortgesetzt | Wedbush | Outperform |
2022-03-15 | Hochstufung | BofA Securities | Neutral → Buy |
2022-03-01 | Eingeleitet | Citigroup | Buy |
2022-02-14 | Hochstufung | Oppenheimer | Perform → Outperform |
2022-01-06 | Eingeleitet | Cowen | Market Perform |
2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
2021-10-20 | Herabstufung | BofA Securities | Buy → Neutral |
2021-03-30 | Herabstufung | Oppenheimer | Outperform → Perform |
2021-03-11 | Fortgesetzt | Stifel | Buy |
2020-12-17 | Eingeleitet | Berenberg | Buy |
2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
2020-03-20 | Eingeleitet | Oppenheimer | Outperform |
2019-10-11 | Eingeleitet | Morgan Stanley | Overweight |
2019-03-25 | Eingeleitet | Evercore ISI | Outperform |
2019-01-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-01-24 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
2018-06-26 | Eingeleitet | Stifel | Buy |
2018-04-02 | Bestätigt | Leerink Partners | Mkt Perform |
2017-05-11 | Eingeleitet | JP Morgan | Overweight |
2017-03-09 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
2017-02-09 | Eingeleitet | Credit Suisse | Outperform |
2016-09-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Ascendis Pharma A S Adr Aktie (ASND) Neueste Nachrichten
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Canaccord holds Ascendis Pharma stock at $84 target - Investing.com
BofA raises Ascendis Pharma stock target to $216 - Investing.com
Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN
Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl
BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India
Ascendis Pharma stock rises following FDA priority review - Investing.com
FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com
Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com
Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India
Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India
Ascendis Pharma grants new employee warrants - Investing.com
Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India
Ascendis Pharma reports growth in achondroplasia trial - Investing.com
Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX
Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com
Ascendis Pharma A/S ADR (ASND) stock on the rise: An overview - uspostnews.com
Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com
Banco Macro ADR Earns Relative Strength Rating Upgrade - inkl
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
UBS maintains Ascendis Pharma stock Buy rating, $196 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView
Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com
Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com
Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com
Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily
Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl
Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com
ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com
Ascendis Pharma launches $25 million share buyback - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa
Finanzdaten der Ascendis Pharma A S Adr-Aktie (ASND)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):